ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: Home > Cell > Fc gamma RIIA / CD32a > SCJUR-STF069

Human CD32a (131H) (Luc) Jurkat Reporter Cell

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The Human CD32a (131H) (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human CD32a (131H) (Uniprot: P12318-1) exhibiting a higher affinity for IgG2 isotypes compared to CD32a-131R, which can use to evaluate ADCP activity of antibodies in the presence of corresponding target cells. When co-cultured with a target cell and relevant antibody, the antibody simultaneously binds the target cell antigen and CD32a (131H) receptor on the surface of Human CD32a (131H) Jurkat Reporter Cell, resulting in receptor clustering, intracellular signaling and NFAT-mediated luminescence.
  • Application

    • Determination of ADCP activity induced by antibodies.

     Fc gamma RIIA / CD32a Assay Principles

  • Growth Properties
    Suspension
  • Selection Marker
    Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)
  • Complete Growth Medium
    RPMI-1640 + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.

Receptor Assay
 Fc gamma RIIA / CD32a FACS

Expression analysis of human CD32a on Human CD32a (131H) (Luc) Jurkat Reporter Cell by FACS.
Cell surface staining was performed on Human CD32a (131H) (Luc) Jurkat Reporter Cell or negative control cell using PE-labeled anti-human CD32a antibody.

Application
 Fc gamma RIIA / CD32a APPLICATION

ADCP response to anti-human CD20 antibody (RLU).
Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 was approximately 0.1054 μg/mL.

 Fc gamma RIIA / CD32a APPLICATION

ADCP response to anti-human CD20 antibody (FOLD).
Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 277.90.

Passage Stability
 Fc gamma RIIA / CD32a PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human CD32a (131H) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human CD20 antibody in the presence of Raji cells. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-23.

Please contact us if you are interested in related cell pool service.

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $10550.00

Drug Candidate Licensing

more

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:2 Details
  • Latest Research Phase:Phase 1 Clinical

Datasheet & Documentation

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop